Bionano Genomics, Inc.

Bionano Genomics, Inc. announced the appointment of Alex Hastie, Ph.D. as its new Chief Scientific Officer, effective July 20, 2026. Dr. Hastie, who previously spent 14 years at Bionano as a foundational figure in its scientific evolution, will lead the company's global scientific strategy, innovation roadmap, and research initiatives. His return is expected to strengthen Bionano's commitment to expanding the research application of its genome analysis technologies and developing clinical applications, receiving overwhelmingly positive responses from the scientific community.

Bionano Genomics announced a substantial increase in studies featuring its Optical Genome Mapping (OGM) technology at the 2026 European Society of Human Genetics (ESHG) conference, indicating expanding global adoption. The number of OGM studies grew by 67% to 35, with authorship from 17 countries across five global markets. Researchers highlighted OGM's ability to resolve complex genomic rearrangements and identify cryptic structural variants, particularly in rare and constitutional genetic disorders, hematologic malignancies, and hereditary cancer.

Bionano Genomics, Inc. announced that Dr. Alka Chaubey has resigned from her position as Chief Medical Officer. Her resignation is effective July 5, 2026.

Bionano Genomics, Inc. announced the full retirement and cancellation of its $20 million Senior Secured Convertible Debentures, originally issued in May 2024. The company utilized cash on hand to complete this debt restructuring, resulting in no outstanding secured debt obligations. This action releases all liens on company assets and extinguishes associated restrictive covenants, providing Bionano with significantly enhanced financial and operational flexibility to focus on its commercial strategy and optical genome mapping adoption.

Bionano Genomics announced the publication of a peer-reviewed study in Modern Pathology demonstrating that its optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases. This detection rate is nearly double the 55% achieved by conventional cytogenetic analysis. Conducted by researchers at MD Anderson Cancer Center and Johns Hopkins University School of Medicine, the 91-subject study highlighted OGM's ability to provide additional genomic insights beyond standard methods in approximately 70% of cases, including 21 newly identified gene fusions. The findings underscore OGM's potential to transform the study and understanding of this aggressive blood cancer and streamline genomic analysis workflows.

Bionano Genomics, Inc. reported a net loss of $8.3 million for the first quarter of 2026, a significant increase from $3.1 million in the prior year, despite a modest 3.6% rise in total revenue to $6.7 million. The company also disclosed substantial doubt about its ability to continue as a going concern within the next twelve months, highlighting its reliance on securing additional funding to address recurring losses and negative cash flows.

Bionano Genomics reported its first quarter 2026 financial results, with total revenue increasing 4% to $6.7 million and consumables revenue growing 20% to $3.9 million. The company also saw a 17% increase in nanochannel array flow cell sales and an improvement in gross margin to 49%. Operating expenses decreased by 2% to $11.1 million. Key business highlights include the effectiveness of a new Category I CPT code for OGM and a 47% increase in payment for another OGM-related CPT code, alongside expanding evidence and adoption of its optical genome mapping technology. The company provided Q2 2026 revenue guidance of $7.5-$7.8 million and full-year guidance of $30-$33 million.

Bionano Genomics, Inc. announced a leadership transition, with R. Erik Holmlin, Ph.D. terminated as President and Chief Executive Officer, effective May 5, 2026. Dr. Holmlin also resigned from the Board of Directors. Albert A. Luderer, Ph.D., the current Chairman, has been appointed Interim Chief Executive Officer and interim principal financial officer. The company will initiate a search for a permanent CEO, and Christopher J. Twomey was appointed Lead Independent Director.